Working… Menu

Embryo Aneuploidies and Ovarian Stimulation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00707525
Recruitment Status : Completed
First Posted : July 1, 2008
Last Update Posted : March 26, 2010
Information provided by:
Instituto Valenciano de Infertilidad, IVI VALENCIA

Brief Summary:

There is a considerable concern about the effects of controlled ovarian hyperstimulation (COH) for In Vitro Fertilization- Embryo Transfer (IVF-ET) on embryo quality and on the incidence of chromosomal abnormalities in oocytes and embryos.

The main question remaining is if COH may increase the aneuploidies rate in young and healthy women. Therefore, the primary endpoint of the present study is to analyse the incidence of chromosomal abnormalities in this group of patients (oocyte donors), either in oocytes obtained after a natural cycle or in those retrieved after a COH cycle. To get rid of the male factor influence, donated sperm will be used.

Condition or disease Intervention/treatment Phase
Embryo Aneuploidies Procedure: Preimplantation Genetic Diagnosis Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Incidence of EmbyoO Aneuploidies in Natural Versus Stimulated Cycles in the Same Women.
Study Start Date : February 2008
Actual Primary Completion Date : February 2010
Actual Study Completion Date : February 2010

Arm Intervention/treatment
No Intervention: 1
Natural cycle oocyte donation
Active Comparator: 2

Stimulated cycle oocyte donation.

  • Long protocol down-regulation with a GnRH agonist, starting on the midluteal phase of the previous cycle with leuprolide acetate (0.2mg/day).
  • Once evidence of downregulation is documented, leuprolide will be halved to 0.1 mg daily.
  • COH with be carried on with gonadotropins (150UI/day of rFSH and 75 UI/day of HP-hMG). The dose can be adjusted according to ovarian response as judged by ultrasound and by serum oestradiol (E 2 ) concentrations.
Procedure: Preimplantation Genetic Diagnosis
Preimplantation Genetic Diagnosis (PGD) is performed on the embryos resulting from these natural and stimulated cycles.

Primary Outcome Measures :
  1. Embryo aneuploidies [ Time Frame: 2 cycles ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 35 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Donor Inclusion Criteria:

  • 18 to 35 years old.
  • BMI: 18-25Kg/m2
  • Regular menstrual cycles
  • Normal kariotype
  • No previous controlled ovarian hyperstimulation (COH) treatments.

Donor Exclusion Criteria:

  • Endometriosis
  • Policystic ovarian syndrome
  • Recurrent miscarriages.

Recipient Inclusion Criteria

  • Aged until 45 years old
  • No systemic diseases
  • Following egg and sperm donation treatment.

Recipient exclusion criteria:

  • Uterine disease (polyps, myomas, mullerian defects)
  • Recurrent miscarriages.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00707525

Layout table for location information
Instituto Valenciano de Infertilidad
Valencia, Spain, 46015
Sponsors and Collaborators
Instituto Valenciano de Infertilidad, IVI VALENCIA

Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Dr. Elena Labarta, Instituto Valenciano de Infertilidad, Spain Identifier: NCT00707525     History of Changes
Other Study ID Numbers: 0607-C-M09-EL
First Posted: July 1, 2008    Key Record Dates
Last Update Posted: March 26, 2010
Last Verified: March 2010
Keywords provided by Instituto Valenciano de Infertilidad, IVI VALENCIA:
aneuploidies, natural cycle, stimulated cycle, preimplantation genetic diagnosis
Additional relevant MeSH terms:
Layout table for MeSH terms
Chromosome Aberrations
Pathologic Processes